Loading
Pharmacology and Obesity Treatment / Diabetes Treatment and Management · Journal article
Endocrinology Diabetes & Metabolism · August 11, 2026
A consensus or society position rather than new primary data.
This narrative review synthesizes evidence on combination pharmacotherapies for obesity, mapping agents to three domains of energy homeostasis to guide mechanistic interpretation. Fixed-dose combinations and multi-agonist peptides show greater weight loss than monotherapy but carry increased adverse-event risks; add-on regimens and drug-procedure pairings generally demonstrate additive rather than synergistic benefit. The authors conclude that combination approaches may extend precision obesity care but require careful, phenotype-guided patient selection and comparison against potent monotherapies.
Narrative review. Clinical trials and observational studies of obesity pharmacotherapy combinations; specific trial populations not detailed in abstract.. Intervention: Fixed-dose combinations (phentermine-topiramate, naltrexone-bupropion), multi-agonist peptides (GLP-1, GIP, glucagon, amylin), add-on regimens (GLP-1 agonists with approved obesity medications or SGLT-2 inhibitors), and multimodal strategi…. Compared with: Individual drug components and monotherapy; specific comparators vary by combination strategy studied..
Fixed-dose combinations (phentermine-topiramate, naltrexone-bupropion) yield greater weight loss than individual components but increase gastrointestinal, cardiovascular and neuropsychiatric risks. Multi-agonist peptides (integrating GLP-1, GIP, glucagon, or amylin) deliver double-digit weight loss and improve glycemic and cardiometabolic profiles, with increased risk of gastrointestinal adverse events. Add-on regimens (GLP-1 agonists combined with approved obesity medications or SGLT-2 inhibitors) and multimodal strategies (drugs paired with bariatric or endoscopic procedures) show additive rather than truly synergistic effects on weight loss.
Multi-agonist peptides (integrating GLP-1, GIP, glucagon, or amylin) deliver double-digit weight loss and improve glycemic and cardiometabolic profiles, with increased risk of gastrointestinal adverse events.
Clinicians should recognize that combination pharmacotherapy for obesity generally provides additive benefits with increased complexity, costs and adverse-event burden; phenotype-guided selection informed by multi-omics and behavioural insights may identify patients who benefit sustainably, but current evidence does not demonstrate superiority over potent monotherapies and warrants comparative trials.
A narrative review synthesizing mechanisms and clinical evidence for obesity pharmacotherapy combinations, offering expert interpretation of existing trials to inform clinical practice rather than reporting original trial results.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize that combination pharmacotherapy for obesity generally provides additive benefits with increased complexity, costs and adverse-event burden; phenotype-guided selection informed by multi-omics and behavioural insights may identify patients who benefit sustainably, but current evidence does not demonstrate superiority over potent monotherapies and warrants comparative trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
INTRODUCTION: Conventional single-agent drugs yield modest, plateauing weight loss and often lead to weight regain. Combination pharmacotherapy is a logical next step to target complementary pathways of weight control while reducing toxicity and treatment burden. This review synthesises mechanisms and clinical evidence for fixed-dose combinations, multi-agonist peptides, add-on regimens and multimodal strategies integrating pharmacotherapy with procedures. METHODS: We conducted a narrative review of clinical trials and observational studies on approved and emerging obesity pharmacotherapy combinations, focusing on mechanistic complementarity, efficacy, safety and practical implementation. Agents were mapped to three domains of energy homeostasis-homeostatic appetite regulation, hedonic-reward circuitry and peripheral metabolic effector pathways-to inform interpretation of combination strategies. RESULTS: Fixed-dose combinations such as phentermine-topiramate and naltrexone-bupropion yield greater weight loss than their individual components but also carry gastrointestinal, cardiovascular and neuropsychiatric risks. Multi-agonist peptides integrating GLP-1, GIP, glucagon, or amylin deliver double-digit weight loss and improve glycemic and cardiometabolic profiles, but increase the risk of gastrointestinal adverse events, requiring close monitoring. Add-on regimens that combine GLP-1 agonists with approved obesity medications or SGLT-2 inhibitors, and multimodal strategies that pair drugs with bariatric or endoscopic procedures, generally show additive rather than truly synergistic effects on weight loss. CONCLUSIONS: Available data suggest that combination pharmacotherapy can extend current approaches to precision obesity care, generally providing additive benefits alongside increased regimen complexity, costs and adverse-event risks. Thoughtful, phenotype-guided selection and comparative studies versus potent monotherapies, enriched by multi-omics and behavioural insights, may clarify which patients benefit most and sustainably from these strategies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.